SEOUL, Aug. 12 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that its two kinds of diagnostic kits for the novel coronavirus began sales in the United States. A point-of-care antigen testing (POCT) kit, dubbed “Sampinute,” co-developed by local health care firm BBB, was commercialized following emergency approval by the U.S. Food [...]
SEOUL, Aug. 7 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday that its net profit jumped 77 percent on-year in the second quarter on the back of robust sales of its blockbuster biosimilar, Truxima. Net profit came to 138.6 billion won (US$117 million) during the April-June period on a consolidated [...]
SEOUL, July 20 (Korea Bizwire) — Celltrion, a leading pharmaceutical firm in South Korea, said Monday that it is preparing to start commercial production of its antibody treatment for the new coronavirus as early as September. Celltrion plans to begin the production of its antiviral antibody treatment for the COVID-19 virus at its plant in [...]
SEOUL, July 17 (Korea Bizwire) — South Korea approved phase one clinical trials for Celltrion Inc.’s coronavirus antibody treatment substance, the country’s drug safety agency said Friday. The move to test CT-P59 marks the first time that a locally made genetic recombination antibody treatment material has been given the green light to be used on [...]
SEOUL, July 9 (Korea Bizwire) — The chief of the pharmaceutical group Celltrion saw the value of his stock holdings rise the most among the heads of South Korea’s major business groups in the first half, data showed Thursday. Seo Jung-jin held 5.85 trillion won (US$4.9 billion) worth of listed shares in group flagship Celltrion [...]
SEOUL, June 16 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that it will export two kinds of diagnostic kits for the novel coronavirus starting next month. A point-of-care antigen testing (POCT) kit, co-developed by local health care firm BBB, will first be commercialized in countries that lack diagnostic infrastructure, Celltrion said. [...]
SEOUL, June 11 (Korea Bizwire) — Celltrion Inc., a South Korean biopharmaceutical firm, announced Thursday that it has signed an agreement to acquire the business rights for 18 brands of Takeda Pharmaceutical of Japan in the Asia-Pacific region. Under the 332.4 billion won (US$278.2 million) deal, Celltrion is set to secure the patent, trademark and [...]
SEOUL, June 10 (Korea Bizwire) — An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that it will begin a study on the treatment efficacy of its biosimilar Remsima on the novel coronavirus. Celltrion Healthcare, which handles Celltrion’s overseas business, said the trial study of Remsima, a biosimilar drug to treat autoimmune diseases, [...]
SEOUL, June 1 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. announced Monday that positive results were shown for its treatment for the novel coronavirus in animal testing. The company said its antiviral antibody treatment showed a 100-fold reduction in the viral load of SARS-CoV-2, the virus known to be causing COVID-19, in an [...]
SEOUL, May 27 (Korea Bizwire) — South Korean pharmaceutical companies have joined the global race to develop a vaccine for the novel coronavirus, but none of them have received approval for clinical trials for a vaccine or treatment candidates from the country’s drug safety agency. Celltrion Inc., a major pharmaceutical giant, has announced that it [...]